In our last update, we mentioned NanoViricides' application for FDA orphan drug status for its dengue drug, DengueCide. Successfully receiving this designation, which is designed to encourage development of rare and tropical disease therapies, would greatly speed DengueCide's commercialization ramp. This would not only be a boon for NanoViricides and its investors, but for dengue patients as well.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.